Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$8.03 USD
-0.34 (-4.06%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $8.04 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Ocular Therapeutix, Inc. [OCUL]
Reports for Purchase
Showing records 41 - 60 ( 89 total )
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Preliminary 3Q20 Product Revenue Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
First Patients Dosed in OTX-CSI Phase 2 Dry Eye Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Medicare Coverage of DEXTENZA Insertion Expanded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
2Q20 Financial Results Reported; Reiterate Buy; Raising PT to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
DEXTENZA Insert Wins Additional Medicare Coverage; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
2Q20 Preliminary Results; New Dry Eye Candidate; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Reimbursement Established for Intracanalicular Inserts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
OTX-TKI Phase 1 Trial Update; Financing Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
First Patient Dosed in Dry Eye Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
DEXTENZA Meets Phase 3 Primary Endpoints; Reiterate Buy; Raising PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
COVID-19 Has No Impact on Total Valuation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
4Q and Full-Year 2019 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Preliminary 4Q19 Results; Interim Phase 1 OTX-TKI Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Positive Glaucoma Data Presented; Reiterate Buy; Raising PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
3Q19 Results Reported; Reiterate Buy; Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Modifying Our 4Q19 DEXTENZA Sales Projections; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
First Patients Dosed in Allergic Conjunctivitis Pivotal Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
J-code Assigned for DEXTENZA Reimbursement; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y